Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leonie A Cluse

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Molecular Cancer Therapeutics|May 17, 2008
Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsinAndrea Newbold, Ralph K Lindemann, Leonie A Cluse, et al.
Cancer Research|October 26, 2013
An intact immune system is required for the anticancer activities of histone deacetylase inhibitorsAlison C West, Stephen R Mattarollo, Jake Shortt, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 22, 2002
The Rac2 guanosine triphosphatase regulates B lymphocyte antigen receptor responses and chemotaxis and is required for establishment of B-1a and marginal zone B lymphocytesBen A Croker, David M Tarlinton, Leonie A Cluse, et al.
Immunology and Cell Biology|June 18, 2002
Rac2-deficient mice display perturbed T-cell distribution and chemotaxis, but only minor abnormalities in T(H)1 responsesBen A Croker, Emanuela Handman, John D Hayball, et al.
Cell Death & Disease|January 6, 2026
Dual Bcl-2/Bcl-xl inhibition via AZD0466 combines with immune checkpoint blockade to enhance anti-tumour activityDane M Newman, Courtney L Andersen, Leonie A Cluse, et al.
Methods in Molecular Biology (Clifton, N.J.)|January 12, 2018
A Comprehensive Protocol Resource for Performing Pooled shRNA and CRISPR ScreensLeonie A Cluse, Iva Nikolic, Deborah Knight, et al.
Blood|December 9, 2008
Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitorsKate F Whitecross, Amber E Alsop, Leonie A Cluse, et al.
Blood|April 23, 2009
The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacyLeigh Ellis, Michael Bots, Ralph K Lindemann, et al.
Cancer Research|March 15, 2011
Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737Adrian P Wiegmans, Amber E Alsop, Michael Bots, et al.
Molecular Cancer Therapeutics|July 14, 2016
BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family MembersSimon J Hogg, Andrea Newbold, Stephin J Vervoort, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Molecular Cancer Therapeutics|May 17, 2008
Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsinAndrea Newbold, Ralph K Lindemann, Leonie A Cluse, et al.
Cancer Research|October 26, 2013
An intact immune system is required for the anticancer activities of histone deacetylase inhibitorsAlison C West, Stephen R Mattarollo, Jake Shortt, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 22, 2002
The Rac2 guanosine triphosphatase regulates B lymphocyte antigen receptor responses and chemotaxis and is required for establishment of B-1a and marginal zone B lymphocytesBen A Croker, David M Tarlinton, Leonie A Cluse, et al.
Immunology and Cell Biology|June 18, 2002
Rac2-deficient mice display perturbed T-cell distribution and chemotaxis, but only minor abnormalities in T(H)1 responsesBen A Croker, Emanuela Handman, John D Hayball, et al.
Cell Death & Disease|January 6, 2026
Dual Bcl-2/Bcl-xl inhibition via AZD0466 combines with immune checkpoint blockade to enhance anti-tumour activityDane M Newman, Courtney L Andersen, Leonie A Cluse, et al.
Methods in Molecular Biology (Clifton, N.J.)|January 12, 2018
A Comprehensive Protocol Resource for Performing Pooled shRNA and CRISPR ScreensLeonie A Cluse, Iva Nikolic, Deborah Knight, et al.
Blood|December 9, 2008
Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitorsKate F Whitecross, Amber E Alsop, Leonie A Cluse, et al.
Blood|April 23, 2009
The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacyLeigh Ellis, Michael Bots, Ralph K Lindemann, et al.
Cancer Research|March 15, 2011
Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737Adrian P Wiegmans, Amber E Alsop, Michael Bots, et al.
Molecular Cancer Therapeutics|July 14, 2016
BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family MembersSimon J Hogg, Andrea Newbold, Stephin J Vervoort, et al.
Pageof 3